TL;DR
A systematic review and meta-analysis covering nearly 15.9 million people found ADHD was associated with a 71% higher risk of all-cause mortality, as well as higher risks for several specific causes of death. ADHD medication use correlated with lower all-cause mortality, but that analysis included only three studies and cannot establish that medication caused the difference.
A systematic review and meta-analysis of 19 studies involving 15,920,970 participants found that people with ADHD had a 71% higher relative risk of all-cause mortality than comparison groups. The analysis also found higher risks of suicide, injury and natural-cause death; a separate association between ADHD medication use and lower mortality was based on only three studies and does not show that medication caused the reduction.
Researchers led by Joshua Stott, PhD, of University College London, reported an all-cause mortality hazard ratio of 1.71 for people with ADHD (95% confidence interval 1.31 to 2.24). The review, published in JAMA Network Open, examined quantitative studies reporting overall or cause-specific mortality across age groups. The search covered peer-reviewed research available through July 2025.
The pooled analyses found elevated relative risks for suicide (hazard ratio 1.89), unintentional or intentional injury (1.55) and natural-cause mortality (1.27). These are comparisons between groups in the included studies, not estimates that describe any one person’s likelihood of dying. The researchers said all studies in the review showed mortality was higher in the ADHD groups, although the size of the association varied.
In three studies examining medication use, people with ADHD who used ADHD medication had a lower all-cause mortality risk than comparison participants (hazard ratio 0.75). The authors cautioned that this result may be affected by differences between treated and untreated people, including healthcare access, illness severity, socioeconomic circumstances, treatment adherence and co-existing psychiatric conditions.
Mortality Findings and ADHD Care
The findings add evidence that mortality differences associated with ADHD appear across several causes of death, rather than being limited to one category. The authors discussed possible pathways, including impulsivity and risk-taking that may contribute to injuries, co-existing depression associated with suicide risk, and health or access factors that could affect natural-cause mortality. These are possible explanations, not causes established by the review.
The results may also sharpen attention to the identification and care of people whose ADHD has not been diagnosed. Stott told MedPage Today that the findings do not mean everyone with ADHD will die young or that increased mortality is inherent or unchangeable. He said they support access to accurate diagnosis and treatment. The study itself did not test a particular screening program or show that diagnosis or treatment prevents deaths.
For readers, the key distinction is between a group-level association and an individual forecast. A higher relative risk in pooled studies does not mean a person with ADHD will experience an early death. The medication result is similarly limited: it suggests an association worth studying, not proof of a protective effect.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Review
The research team assessed studies using several ways of defining ADHD, including clinical diagnostic criteria, self-identification, trait measures and genetic risk scores. Twelve of the 19 studies supplied outcomes that could be pooled in meta-analyses. The all-cause analysis included nine studies; suicide included five; injury included four; natural-cause mortality included three; and medication use and all-cause mortality included three.
The combined sample was 63.9% male, and the studies came from different cultural and healthcare settings. The authors noted possible differences in diagnostic practices and access to care, as well as gender imbalances. Statistical heterogeneity was substantial in the first four analyses, meaning the size of the observed associations varied across studies. The direction of the findings was consistent, the researchers said, but variation limits how uniformly the pooled estimates apply.
Earlier research had also reported elevated mortality among people with ADHD, and some studies had suggested a life-expectancy gap. This review broadened the evidence base across ages and mortality outcomes; it does not establish that ADHD itself directly causes the observed differences.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, PhD, lead author, speaking to MedPage Today
ADHD safety and injury prevention products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Risk Estimates
The review reports associations and cannot determine whether ADHD directly caused higher mortality. Differences in study populations, ADHD definitions, healthcare settings and other factors may influence the estimates. The researchers reported substantial heterogeneity in most pooled analyses, indicating that effect sizes varied among studies.
The medication finding is especially uncertain because it rests on only three studies. People receiving treatment may differ from those not receiving it in health status, access to care, symptom severity and other characteristics. The analysis cannot separate those factors from any potential effect of medication. The review also does not identify which interventions, if any, would reduce the mortality differences, or how well the pooled estimates apply to specific age, gender or cultural groups.
As an affiliate, we earn on qualifying purchases.
Further Study of Care and Outcomes
The review does not announce a specific follow-up study or policy change. Its findings point to the need for research that can better distinguish the effects of ADHD, co-existing conditions and access to healthcare, and to evaluate the medication association using evidence beyond three studies. Future analyses could also examine how risks vary by age, gender, ADHD definition and cause of death.
In the meantime, the authors’ stated implication is that people who may have ADHD should have access to accurate assessment and care. The review does not prescribe a treatment approach or establish that any particular treatment lowers mortality. Further evidence will be needed before the medication association can be interpreted as a treatment effect.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the review find about ADHD and mortality?
Across a pooled analysis, ADHD was associated with a 71% higher relative risk of all-cause mortality than comparison groups. The review also found higher relative risks for suicide, injury and natural-cause mortality. These group comparisons do not predict an individual person’s outcome.
Does this mean everyone with ADHD will die younger?
No. Lead author Joshua Stott told MedPage Today that the findings do not mean everyone with ADHD will die young or that increased mortality is inevitable. The study reports associations across groups, not a personal prognosis.
Did ADHD medication lower the risk of death?
Medication use was associated with a lower all-cause mortality risk in an analysis based on three studies. The researchers cautioned that differences between treated and untreated people could explain some or all of the association, so the finding does not prove medication caused a reduction.
What causes the higher mortality association?
The review does not establish a single cause. Its authors discussed possible contributions from injury risk, co-existing mental health conditions, smoking and alcohol use, healthcare barriers, cardiovascular disease and metabolic disorders. Those pathways were proposed explanations, not causes proven by the analysis.
How large was the evidence base?
The review included 19 studies and 15,920,970 participants; 12 studies provided results for pooled analyses. The medication analysis included only three studies, and several analyses showed variation in results across the studies included.
Source: rss
